Last quarter (Q3 2023), Relmada Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Relmada Therapeutics's net income was $-22.00M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Jun 19	Jun 18
Total Revenue	$ 96.40K	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	$ 29.40M	-	-	-	-	-
Gross Profit	$ -29.31M	-	-	-	-	-
Operating Expense	$ -5.43M	$ 161.25M	$ 125.70M	$ 60.84M	$ 12.73M	$ 6.92M
Operating Income	$ -71.98M	$ -161.25M	$ -125.70M	$ -60.84M	$ -12.73M	$ -6.92M
Net Non Operating Interest Income Expense	$ 9.79M	$ 2.66M	$ 1.20M	$ 1.40M	$ -761.04K	$ -1.34M
Other Income Expense	$ -1.15M	$ 4.81M	$ 1.25M	$ -16.95K	$ -3.83M	$ -706.55K
Pretax Income	$ -69.38M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M	$ -8.96M
Tax Provision	$ -6.20M	$ 6.20M	$ 0.00	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -69.38M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M	$ -8.96M
Basic EPS	$ -4.17	$ -5.30	$ -7.16	$ -3.81	$ -2.74	$ -2.86
Diluted EPS	$ -7.47	$ -5.30	$ -7.16	$ -3.81	$ -2.74	$ -2.86
Basic Average Shares	$ 119.89M	$ 29.63M	$ 17.55M	$ 15.59M	$ 6.31M	$ 3.14M
Diluted Average Shares	$ 119.89M	$ 29.63M	$ 17.55M	$ 15.59M	$ 6.31M	$ 3.14M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 23.98M	$ 161.25M	$ 125.70M	$ 60.84M	$ 12.73M	$ 6.92M
Net Income From Continuing And Discontinued Operation	$ -125.69M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M	$ -8.96M
Normalized Income	$ -55.29M	$ -130.42M	-	$ -59.44M	$ -13.49M	$ -8.25M
Interest Expense	-	-	-	-	-	-
EBIT	$ -77.48M	$ -159.70M	$ -126.95M	$ -60.84M	$ -12.73M	$ -6.92M
EBITDA	$ -77.48M	$ -159.70M	$ -126.95M	$ -60.83M	$ -12.72M	$ -6.91M

Currency in USD

Relmada Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing